Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint

Tingting Tang(Temple University), Xiang Cheng(Union Hospital), Billy Truong(Temple University), Lizhe Sun(First Affiliated Hospital of Xi'an Jiaotong University), Xiaofeng Yang(Temple University), Hong Wang(Temple University)
Pharmacology & Therapeutics
October 20, 2020
10.1016/j.pharmthera.2020.107709
Cited by 268Open Access
Full Text

Abstract

Related Papers

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Yujie Li, Qin Jiang, Guo-Fan Cao et al.|Cellular Physiology and Biochemistry|2015|16.3k
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Volker Henn, Joseph R. Slupsky, Michael Gräfe et al.|Nature|1998|2.1k
The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review
U. Schönbeck RID ID Correspondi, Peter Libby|Cellular and Molecular Life Sciences|2001|737
Immunotoxicology and immunopharmacology
|Food and Chemical Toxicology|1986|422
CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
William G. Wierda, Mark J. Cantwell, Sandra J. Woods et al.|Blood|2000|338